| ACTG 384 |
25 |
14.8 |
Treatment, Double-Blind, Pharmacokinetics Study |
Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection |
| ACTG 388 |
6 |
3.6 |
Treatment, Open Label, Safety Study |
A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater Than or Equal to 80,000 HIV RNA Copies/Ml in Plasma |
| ACTG 5015 |
5 |
3.0 |
Treatment, Efficacy Study |
A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging |
| ACTG 5073 |
6 |
3.6 |
Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation |
| ACTG 5095 |
35 |
20.7 |
Treatment, Active Control, Safety/Efficacy Study |
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection |
| ACTG 5142 |
21 |
12.4 |
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection |
| ACTG 5164 |
16 |
9.5 |
Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy |
| ACTG 5175 |
7 |
4.1 |
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals From Resource-Limited Settings (PEARLS) Trial |
| ACTG 5202 |
28 |
16.6 |
Other, Randomized, Active Control, Parallel Assignment, Safety/Efficacy Study |
A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects |
| Abbott M97 |
7 |
4.1 |
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients |
| Gilead 903 |
7 |
4.1 |
Treatment, Parallel Assignment |
A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz Versus Stavudine, Lamivudine, and Efavirenz |
| Gilead 934 |
1 |
0.5 |
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Phase 3/Randomized/Open-Label Study of the Treatment of Antiretroviral-Naive HIV-1-Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs. Combivir (Lamivudine/Zidovudine) and Efavirenz |
| KLEAN |
5 |
3.0 |
Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700 mg BID) Plus Ritonavir (100 mg BID) Versus Lopinavir/Ritonavir (400 mg/100 mg BID) When Administered in Combination With the Abacavir/Lamivudine (600 mg/300 mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks |
